Susquehanna International Group, LLP Obs Eva Sa Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.34 - $2.08 $62,831 - $97,529	-46,889 Reduced 46.59%	53,757 $87,000
Q1 2022 May 16, 2022	SELL	$1.1 - $2.17 $51,467 - $101,532	-46,789 Reduced 31.74%	100,646 $152,000
Q4 2021 Feb 14, 2022	BUY	$1.99 - $3.1 $89,800 - $139,890	45,126 Added 44.11%	147,435 $293,000
Q3 2021 Nov 15, 2021	SELL	$2.47 - $3.34 $324,061 - $438,204	-131,199 Reduced 56.19%	102,309 $318,000
Q2 2021 Aug 11, 2021	SELL	$2.56 - $3.35 $3,499 - $4,579	-1,367 Reduced 0.58%	233,508 $708,000
Q1 2021 May 17, 2021	BUY	$2.01 - $5.05 $436,077 - $1.1 Million	216,954 Added 1210.61%	234,875 $763,000
Q3 2020 Nov 16, 2020	BUY	$2.46 - $6.15 $44,085 - $110,214	17,921 New	17,921 $44,000

88K

Ticker OBSV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,499,200
Description
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometrio...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.